Institution
Research Triangle Park
Nonprofit•Durham, North Carolina, United States•
About: Research Triangle Park is a nonprofit organization based out in Durham, North Carolina, United States. It is known for research contribution in the topics: Population & Environmental exposure. The organization has 24961 authors who have published 35800 publications receiving 1684504 citations. The organization is also known as: RTP.
Topics: Population, Environmental exposure, Receptor, Poison control, Agonist
Papers published on a yearly basis
Papers
More filters
TL;DR: In this article, the authors provide an overview of experimental work on such systems together with an outline of theoretical studies that have been undertaken to estimate the practical limits to the amount of hydrogen that could be stored per unit weight.
654 citations
TL;DR: Results suggest distinct natural courses of development between DSM-IV insomnia, anxiety, and depression during adolescence, and insomnia may have independent, and potentially etiologically distinct, directional associations with anxiety disorders versus depression.
653 citations
TL;DR: Air pollution monitoring paradigm is rapidly changing due to recent advances in the development of portable, lower-cost air pollution sensors reporting data in near-real time at a high-time resolution, increased computational and visualization capabilities, and wireless communication/infrastructure.
Abstract: The air pollution monitoring paradigm is rapidly changing due to recent advances in (1) the development of portable, lower-cost air pollution sensors reporting data in near-real time at a high-time...
653 citations
TL;DR: Exploratory analyses suggested that APOE ɛ4 non-carriers exhibited cognitive and functional improvement in response to RSG, whereas apolipoprotein E (APOE) genotype carriers showed no improvement and some decline was noted.
Abstract: Mild-to-moderate AD patients were randomized to placebo or rosiglitazone (RSG) 2, 4 or 8 mg. Primary end points at Week 24 were mean change from baseline in AD Assessment Scale-Cognitive (ADAS-Cog) and Clinician's Interview-Based Impression of Change Plus Caregiver Input global scores in the intention-to-treat population (N=511), and results were also stratified by apolipoprotein E (APOE) genotype (n=323). No statistically significant differences on primary end points were detected between placebo and any RSG dose. There was a significant interaction between APOE epsilon4 allele status and ADAS-Cog (P=0.014). Exploratory analyses demonstrated significant improvement in ADAS-Cog in APOE epsilon4-negative patients on 8 mg RSG (P=0.024; not corrected for multiplicity). APOE epsilon4-positive patients did not show improvement and showed a decline at the lowest RSG dose (P=0.012; not corrected for multiplicity). Exploratory analyses suggested that APOE epsilon4 non-carriers exhibited cognitive and functional improvement in response to RSG, whereas APOE epsilon4 allele carriers showed no improvement and some decline was noted. These preliminary findings require confirmation in appropriate clinical studies.
652 citations
651 citations
Authors
Showing all 25006 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Douglas G. Altman | 253 | 1001 | 680344 |
| Lewis C. Cantley | 196 | 748 | 169037 |
| Ronald Klein | 194 | 1305 | 149140 |
| Daniel J. Jacob | 162 | 656 | 76530 |
| Christopher P. Cannon | 151 | 1118 | 108906 |
| James B. Meigs | 147 | 574 | 115899 |
| Lawrence Corey | 146 | 773 | 78105 |
| Jeremy K. Nicholson | 141 | 773 | 80275 |
| Paul M. Matthews | 140 | 617 | 88802 |
| Herbert Y. Meltzer | 137 | 1148 | 81371 |
| Charles J. Yeo | 136 | 672 | 76424 |
| Benjamin F. Cravatt | 131 | 666 | 61932 |
| Timothy R. Billiar | 131 | 838 | 66133 |
| Peter Brown | 129 | 908 | 68853 |
| King K. Holmes | 124 | 606 | 56192 |